Business Description
China Shineway Pharmaceutical Group Ltd
NAICS : 325412
ISIN : KYG2110P1000
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 17.76 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.24 | |||||
Interest Coverage | 174.81 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.16 | |||||
Beneish M-Score | -2.42 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.3 | |||||
3-Year EBITDA Growth Rate | 28.4 | |||||
3-Year EPS without NRI Growth Rate | 29.4 | |||||
3-Year FCF Growth Rate | 8.4 | |||||
3-Year Book Growth Rate | 7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 11.35 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.5 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.57 | |||||
9-Day RSI | 54.44 | |||||
14-Day RSI | 57.8 | |||||
6-1 Month Momentum % | -15.28 | |||||
12-1 Month Momentum % | 9.58 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.48 | |||||
Quick Ratio | 3.14 | |||||
Cash Ratio | 2.56 | |||||
Days Inventory | 295.81 | |||||
Days Sales Outstanding | 68.39 | |||||
Days Payable | 155.92 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 6.2 | |||||
Dividend Payout Ratio | 0.37 | |||||
3-Year Dividend Growth Rate | 19.1 | |||||
Forward Dividend Yield % | 6.2 | |||||
5-Year Yield-on-Cost % | 9.54 | |||||
3-Year Average Share Buyback Ratio | 3 | |||||
Shareholder Yield % | 3.42 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.21 | |||||
Operating Margin % | 22.52 | |||||
Net Margin % | 26.24 | |||||
FCF Margin % | 25.5 | |||||
ROE % | 15.72 | |||||
ROA % | 11.64 | |||||
ROIC % | 32.75 | |||||
3-Year ROIIC % | 201.81 | |||||
ROC (Joel Greenblatt) % | 117.3 | |||||
ROCE % | 20.04 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 6.25 | |||||
Forward PE Ratio | 5.65 | |||||
PE Ratio without NRI | 6.24 | |||||
Shiller PE Ratio | 10.64 | |||||
Price-to-Owner-Earnings | 7.12 | |||||
PEG Ratio | 0.52 | |||||
PS Ratio | 1.64 | |||||
PB Ratio | 0.95 | |||||
Price-to-Tangible-Book | 0.95 | |||||
Price-to-Free-Cash-Flow | 6.42 | |||||
Price-to-Operating-Cash-Flow | 5.86 | |||||
EV-to-EBIT | 0.47 | |||||
EV-to-EBITDA | 0.47 | |||||
EV-to-Revenue | 0.16 | |||||
EV-to-FCF | 0.9 | |||||
Price-to-Projected-FCF | 0.46 | |||||
Price-to-Median-PS-Value | 0.61 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.57 | |||||
Price-to-Graham-Number | 0.5 | |||||
Price-to-Net-Current-Asset-Value | 1.15 | |||||
Price-to-Net-Cash | 1.83 | |||||
Earnings Yield (Greenblatt) % | 214.51 | |||||
FCF Yield % | 16.24 | |||||
Forward Rate of Return (Yacktman) % | 21.09 |